Diamedica Therapeutics Inc., of Minneapolis, said it completed a nonbrokered private placement with an undisclosed U.S. investor, issuing about 10.5 million units at 19 cents each, with each unit consisting of one common share and half of one common share purchase warrant. Gross proceeds totaled about $2 million and will be used to advance the firm's R&D program, including DM199 for the treatment of neurological and kidney diseases, and for general corporate purposes.